Home/Filings/4/0000950170-24-088589
4//SEC Filing

Poulton Stuart 4

Accession 0000950170-24-088589

CIK 0001503802other

Filed

Jul 30, 8:00 PM ET

Accepted

Jul 31, 4:14 PM ET

Size

4.9 KB

Accession

0000950170-24-088589

Insider Transaction Report

Form 4
Period: 2024-07-30
Poulton Stuart
EVP, Chief Development Officer
Transactions
  • Sale

    Common Stock

    2024-07-30$1.06/sh2,883$3,056326,628 total
Footnotes (1)
  • [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

Documents

1 file

Issuer

Karyopharm Therapeutics Inc.

CIK 0001503802

Entity typeother

Related Parties

1
  • filerCIK 0001942597

Filing Metadata

Form type
4
Filed
Jul 30, 8:00 PM ET
Accepted
Jul 31, 4:14 PM ET
Size
4.9 KB